Link Healthcare
Link Healthcare is an Australian specialty pharmaceutical company (founded 1997, Clinigen Group subsidiary) that provides ethical access to over 20 registered and unregistered specialty medicines across oncology, haematology, emergency, and other therapeutic areas to hospitals, prescribers, and pharma partners in the Australasia, Asia, and Africa region.
- Company typePrivate
- Founded1997
- HeadquartersSydney, Australia
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Link Healthcare does
Link Healthcare (legally Link Medical Products Pty Ltd) is an Australian specialty pharmaceutical company founded in 1997 that provides ethical, compliant access to both registered and unregistered specialty medicines across the Australasia, Asia, and Africa (AAA) region. The company sells a portfolio of over 20 registered pharmaceutical products spanning 13+ therapeutic areas—including oncology (ETOPHOS, VEPESID, HYDREA, NATULAN, TRECONDI), haematology, emergency medicine, analgesia/anaesthesia, dermatology, infectious diseases, intensive care, neurology, palliative care, psychiatry, and transplantation—and operates an unregistered medicine access platform covering clinical trial supply, Early Access Programs, medicine shortage sourcing, and discontinued product supply. Underpinning this is in-house pharmacovigilance and regulatory affairs capabilities that enable product licensing and safety monitoring across multiple jurisdictions, including Australia, New Zealand, Japan, Singapore, Hong Kong, and South Africa.
The company's customers are hospitals and healthcare institutions, individual healthcare professionals (prescribers), and pharmaceutical and biotechnology manufacturers seeking regional distribution or clinical trial supply support. Revenue is generated through sale of registered pharmaceutical products (one-time licensing style transactions), facilitation of unregistered medicine supply (licensing/royalty arrangements), and clinical services such as clinical trial supply and Early Access Programs. The company uses a sales-led go-to-market model with direct relationships supported by Australian-registered pharmacist-led medical information services, distributing primarily through direct hospital supply and pharmacy distribution channels. Specific pricing is not publicly disclosed, with prices determined via healthcare system reimbursement and prescription pathways. Link Healthcare has operated as a wholly-owned subsidiary of Clinigen Group since 2015, with the Link Australasia team numbering over 45 employees and headquarters in Warriewood, Sydney.
Link Healthcare firmographics
Firmographics- Name
- Link Healthcare
- Legal name
- Link Medical Products Pty Ltd
- Website
- https://linkhealthcare.com.au
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Link Healthcare is an Australian specialty pharmaceutical company (founded 1997, Clinigen Group subsidiary) that provides ethical access to over 20 registered and unregistered specialty medicines across oncology, haematology, emergency, and other therapeutic areas to hospitals, prescribers, and pharma partners in the Australasia, Asia, and Africa region.
- Ownership category
- akta.pro rank
Link Healthcare industry classification
Industry- Product category
- Specialty Pharmaceuticals Distribution
- NAICS
- Health Care and Social Assistance (62)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Services-Health Services (8000)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Specialty Pharmacies (Complex/High-Cost Therapies) (HLAFALAC), Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO), Generic Hospital & Institutional Products (HLAIABAL)
Keywords
Where Link Healthcare is headquartered
LocationHeadquarters
- HQ city
- Sydney
- HQ country
- Australia
- HQ region
- Oceania
Offices2 records
Markets served
Link Healthcare business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Registered Pharmaceutical Products: Sale and distribution of registered specialty medicines in diverse therapeutic areas including oncology, haematology, emergency medicine, analgesia/anaesthesia, dermatology, endocrinology, infectious diseases, intensive care, rheumatology, neurology, palliative care, psychiatry and transplantation.
- Unregistered Medicine Supply: Facilitating ethical access to unregistered or commercially unavailable medicines, addressing clinical trial supply, global unavailability, medicine shortages, and discontinued products.
- Clinical Services: Services including clinical trial supplies, Early Access Programs, and sourcing medicines for shortages for pharmaceutical and biotech companies.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels2 records
Link Healthcare product offering
Product offeringCore offering
Link Healthcare supplies registered specialty pharmaceutical products across 13 therapeutic areas (oncology, haematology, emergency medicine, analgesia/anaesthesia, dermatology, endocrinology, infectious diseases, intensive care, rheumatology, neurology, palliative care, psychiatry, transplantation) and provides ethical, compliant access to unregistered or commercially unavailable medicines, including clinical trial supply, Early Access Programs, and medicine shortage sourcing. It serves hospitals, healthcare professionals, and pharmaceutical/biotech partners across the Australasia, Asia and Africa (AAA) region as part of Clinigen Group.
Product overview
Link Healthcare is a specialty pharmaceutical company that provides access to both registered and unregistered medicines. The product portfolio consists of over 20 registered pharmaceutical products across diverse therapeutic areas including oncology (ETOPHOS, VEPESID, HYDREA, NATULAN, TRECONDI), haematology (MERCAPTOPURINE-LINK, ALLMERCAP, KAMRAB), emergency medicine (ACETYLCYSTEINE-LINK INJECTION, ADRENALINE-LINK, PENTOTHAL), analgesia/anaesthesia (PENTOTHAL), dermatology (DAPSONE), endocrinology, infectious diseases (FOSCAVIR), intensive care, rheumatology, neurology (MYSOLINE, IMUKIN), palliative care, psychiatry, and transplantation. These products are complemented by services including clinical trial supply, Early Access Programs, unregistered medicine supply, and medicine shortage sourcing. The company operates as part of Clinigen Group and supports healthcare professionals and pharmaceutical industry partners across Australasia.
Differentiator
Problem solved
Functional benefit
Products and services
- ACETYLCYSTEINE-LINK INJECTION A specialist injection product containing acetylcysteine, used for treating paracetamol overdose and as a mucolytic agent. It is a registered pharmaceutical product distributed to hospitals and healthcare institutions in Australia.
- ADRENALINE-LINK Contains adrenaline (epinephrine) acid tartrate, used for emergency treatment of anaphylaxis and cardiac arrest. It is a registered pharmaceutical product supplied to hospitals and emergency care settings.
- ALLMERCAP Contains mercaptopurine monohydrate, used in the treatment of leukemia and inflammatory bowel disease. It is a registered pharmaceutical product.
- ATACAND Contains Candesartan cilexetil, an angiotensin II receptor antagonist used to treat hypertension and heart failure. It is a registered pharmaceutical product.
- ATACAND PLUS Combination product with Hydrochlorothiazide and Candesartan cilexetil, used for treating hypertension. It is a registered pharmaceutical product.
- DAPSONE
Companies that use Link Healthcare
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Link Healthcare technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Link Healthcare partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered flagship and core.
- Clinigen GroupflagshipLink Healthcare became part of Clinigen in 2015, significantly strengthening the Group's global presence and position in the AAA (Australasia, Asia and Africa) region. Clinigen is a rapidly growing specialty pharmaceutical and services company focused on delivering the right medicine, to the right patient, at the right time.
- Biotechnology CompaniescoreStrong partnerships with biotechnology companies across the globe, providing access to specialist medicines and novel pharmaceuticals for the Australasian region.
- Pharmaceutical ManufacturerscorePartnerships with pharmaceutical manufacturers for supply and distribution of specialist registered and unregistered medicines.
- Global Pharmaceutical SupplierscorePartner agreements with suppliers across the globe reviewed regularly to allow supply of products into new geographic regions, reflecting commitment to providing a global network of products and services.
- Equity Pharmaceutical GroupcoreMerger with South Africa's Equity Pharmaceutical group conducted over 2010-2013, expanding geographic presence and product portfolio.
Scale indicators4 records
Recent moves12 records
Expansion highlights4 records
Link Healthcare competitors and assessment
Company assessmentDirect peers
- Tanner Pharma Group: US-based specialty pharma services company providing named-patient access, early access programs and unlicensed medicine supply globally. Closely comparable business model and service offering to Link's unregistered medicine services, with shared pharma/biotech client base.
- Clinigen Group: Parent company and global leader in ethical access to unregistered and specialty medicines. Directly comparable in services (Early Access Programs, clinical trial supply, managed access) and product distribution model; Link is the AAA-region arm of Clinigen's network.
- Econdisc (an Idis Group company): Specialist pharmaceutical company providing named-patient supply, early access and clinical trial supply globally. Closely comparable services model to Link's unregistered medicine access and clinical trial supply offerings, with shared hospital and HCP customer base.
- Durbin PLC: UK-based pharmaceutical distributor specialising in unlicensed medicines, clinical trial supply and global access programs. Comparable in distributing hard-to-source, unlicensed and clinical-trial medicines to hospitals and HCPs across multiple jurisdictions.
- Mawdsley-Brooks & Co: UK-based specialist pharmaceutical distributor and access provider for unlicensed, imported, and clinical-trial medicines. Directly comparable in supplying hard-to-source and unregistered medicines to hospitals and HCPs, with similar regulatory and pharmacovigilance infrastructure.
- Quantum Pharmaceutical: UK-based unlicensed and specials medicines manufacturer and distributor serving hospital pharmacies. Comparable in providing ethical access to medicines not commercially available, including specials manufacturing, clinical trial supply and shortage-sourcing.
Others
- PharmaLex: Global provider of regulatory affairs, pharmacovigilance and quality compliance services to pharma and biotech. Comparable in delivering the in-house regulatory and pharmacovigilance infrastructure (one of Link's stated capabilities) on an outsourced basis to similar clients.
Regional players
- Aspen Pharmacare: South African-headquartered specialty and generic pharmaceutical group with presence across Africa, Australasia and Asia. Comparable in regional multi-market presence (including South Africa, an AAA overlap with Link post-Equity Pharmaceutical merger) and in-licensed mature product strategy.
- Mayne Pharma: Australia-headquartered specialty pharmaceutical company with branded and generic products, complex generics and specialty distribution. Comparable in Australian-domiciled specialty pharma focus and in-licensing-led portfolio growth model.
Broad incumbents
- Swedish Orphan Biovitrum (Sobi): European-listed specialty biopharma focused on rare diseases and specialty medicines with global commercial reach. Comparable in operating a specialty pharma model centred on niche, high-medical-need therapeutics and global partner-led access.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Link Healthcare social profiles
Digital presenceLink Healthcare financial estimates
Financial estimateRevenue estimate
Valuation estimate
Link Healthcare leadership team
Management profileNumber of profiles
Link Healthcare funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Link Healthcare M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Link Healthcare
What does Link Healthcare do?
Link Healthcare supplies registered specialty pharmaceutical products across 13 therapeutic areas (oncology, haematology, emergency medicine, analgesia/anaesthesia, dermatology, endocrinology, infectious diseases, intensive care, rheumatology, neurology, palliative care, psychiatry, transplantation) and provides ethical, compliant access to unregistered or commercially unavailable medicines, including clinical trial supply, Early Access Programs, and medicine shortage sourcing. It serves hospitals, healthcare professionals, and pharmaceutical/biotech partners across the Australasia, Asia and Africa (AAA) region as part of Clinigen Group.
Is Link Healthcare a public or private company?
Link Healthcare is a private company. It is classified as corporate owned and is currently operating.
When was Link Healthcare founded?
Link Healthcare was founded in 1997. It employs 11 to 50 people.
Where is Link Healthcare based?
Link Healthcare is headquartered in Sydney, Australia, in the Oceania region.
How does Link Healthcare make money?
Three revenue lines are on record. Registered Pharmaceutical Products are the primary driver. The others are unregistered Medicine Supply and clinical Services.
Who are Link Healthcare's main competitors?
Direct peers on record are Tanner Pharma Group, Clinigen Group, Econdisc (an Idis Group company), Durbin PLC, Mawdsley-Brooks & Co and Quantum Pharmaceutical. PharmaLex is listed as an others. Regional players are Aspen Pharmacare and Mayne Pharma. Swedish Orphan Biovitrum (Sobi) is listed as a broad incumbent.
Does Link Healthcare have an API?
No public API is recorded for Link Healthcare.
What industry is Link Healthcare in?
Link Healthcare's product category is Specialty Pharmaceuticals Distribution. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAFALAC, Specialty Pharmacies (Complex/High-Cost Therapies). Its NAICS code is 62 and its SIC code is 5122.